Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
NCT ID: NCT00059657
Last Updated: 2006-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
280 participants
INTERVENTIONAL
2001-08-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ecraprost in lipid emulsion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects will already be scheduled to receive a revascularization procedure (e.g., by-pass graft, endovascular procedure, etc.) involving a distal target artery below the knee joint (e.g., below the knee joint popliteal, anterior/posterior tibial, peroneal, plantar, pedal, etc.) as part of their normal standard of care.
Exclusion Criteria
* Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of \< 20 cc/min, or receiving chronic hemodialysis therapy.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mitsubishi Tanabe Pharma Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southhampton, , United Kingdom
Phoenix, Arizona, United States
Tucson, Arizona, United States
Glendale, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Pensacola, Florida, United States
Springfield, Illinois, United States
Shawnee Mission, Kansas, United States
Kenner, Louisiana, United States
Royal Oak, Michigan, United States
Biloxi, Mississippi, United States
Rochester, New York, United States
Durham, North Carolina, United States
San Antonio, Texas, United States
Tacoma, Washington, United States
Birmingham, , United Kingdom
Bristol, , United Kingdom
Dundee, , United Kingdom
Hull, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WFI 01-02
Identifier Type: -
Identifier Source: org_study_id